TY - JOUR
T1 - Five polymorphisms and breast cancer risk: results from the Breast Cancer Association Consortium
AU - Gaudet, Mia M
AU - Milne, Roger L
AU - Cox, Angela
AU - Camp, Nicola J
AU - Goode, Ellen L
AU - Humphreys, Manjeet K
AU - Dunning, Alison M
AU - Morrison, Jonathan
AU - Giles, Graham G
AU - Severi, Gianluca
AU - Baglietto, Laura
AU - English, Dallas R
AU - Couch, Fergus J
AU - Olson, Janet E
AU - Wang, Xianshu
AU - Chang-Claude, Jenny
AU - Flesch-Janys, Dieter
AU - Abbas, Sascha
AU - Salazar, Ramona
AU - Mannermaa, Arto
AU - Kataja, Vesa
AU - Kosma, Veli-Matti
AU - Lindblom, Annika
AU - Margolin, Sara
AU - Heikkinen, Tuomas
AU - Kämpjärvi, Kati
AU - Aaltonen, Kirsimari
AU - Nevanlinna, Heli
AU - Bogdanova, Natalia
AU - Coinac, Irina
AU - Schürmann, Peter
AU - Dörk, Thilo
AU - Bartram, Claus R
AU - Schmutzler, Rita K
AU - Tchatchou, Sandrine
AU - Burwinkel, Barbara
AU - Brauch, Hiltrud
AU - Torres, Diana
AU - Hamann, Ute
AU - Justenhoven, Christina
AU - Ribas, Gloria
AU - Arias, José I
AU - Benitez, Javier
AU - Bojesen, Stig E
AU - Nordestgaard, Børge G
AU - Flyger, Henrik L
AU - Peto, Julian
AU - Fletcher, Olivia
AU - Johnson, Nichola
AU - Dos Santos Silva, Isabel
AU - Australian Ovarian Cancer Study Group
AU - Breast Cancer Association Consortium
N1 - Keywords: Alleles; BH3 Interacting Domain Death Agonist Protein; Breast Neoplasms; Case-Control Studies; Caspase 10; DNA-Binding Proteins; Europe; Female; Genetic Predisposition to Disease; Genotype; Humans; Intracellular Signaling Peptides and Proteins; Logistic Models; Nuclear Proteins; Polymorphism, Single Nucleotide; Risk; Tumor Necrosis Factor-alpha
PY - 2009
Y1 - 2009
N2 - Previous studies have suggested that minor alleles for ERCC4 rs744154, TNF rs361525, CASP10 rs13010627, PGR rs1042838, and BID rs8190315 may influence breast cancer risk, but the evidence is inconclusive due to their small sample size. These polymorphisms were genotyped in more than 30,000 breast cancer cases and 30,000 controls, primarily of European descent, from 30 studies in the Breast Cancer Association Consortium. We calculated odds ratios (OR) and 95% confidence intervals (95% CI) as a measure of association. We found that the minor alleles for these polymorphisms were not related to invasive breast cancer risk overall in women of European descent: ECCR4 per-allele OR (95% CI) = 0.99 (0.97-1.02), minor allele frequency = 27.5%; TNF 1.00 (0.95-1.06), 5.0%; CASP10 1.02 (0.98-1.07), 6.5%; PGR 1.02 (0.99-1.06), 15.3%; and BID 0.98 (0.86-1.12), 1.7%. However, we observed significant between-study heterogeneity for associations with risk for single-nucleotide polymorphisms (SNP) in CASP10, PGR, and BID. Estimates were imprecise for women of Asian and African descent due to small numbers and lower minor allele frequencies (with the exception of BID SNP). The ORs for each copy of the minor allele were not significantly different by estrogen or progesterone receptor status, nor were any significant interactions found between the polymorphisms and age or family history of breast cancer. In conclusion, our data provide persuasive evidence against an overall association between invasive breast cancer risk and ERCC4 rs744154, TNF rs361525, CASP10 rs13010627, PGR rs1042838, and BID rs8190315 genotypes among women of European descent.
AB - Previous studies have suggested that minor alleles for ERCC4 rs744154, TNF rs361525, CASP10 rs13010627, PGR rs1042838, and BID rs8190315 may influence breast cancer risk, but the evidence is inconclusive due to their small sample size. These polymorphisms were genotyped in more than 30,000 breast cancer cases and 30,000 controls, primarily of European descent, from 30 studies in the Breast Cancer Association Consortium. We calculated odds ratios (OR) and 95% confidence intervals (95% CI) as a measure of association. We found that the minor alleles for these polymorphisms were not related to invasive breast cancer risk overall in women of European descent: ECCR4 per-allele OR (95% CI) = 0.99 (0.97-1.02), minor allele frequency = 27.5%; TNF 1.00 (0.95-1.06), 5.0%; CASP10 1.02 (0.98-1.07), 6.5%; PGR 1.02 (0.99-1.06), 15.3%; and BID 0.98 (0.86-1.12), 1.7%. However, we observed significant between-study heterogeneity for associations with risk for single-nucleotide polymorphisms (SNP) in CASP10, PGR, and BID. Estimates were imprecise for women of Asian and African descent due to small numbers and lower minor allele frequencies (with the exception of BID SNP). The ORs for each copy of the minor allele were not significantly different by estrogen or progesterone receptor status, nor were any significant interactions found between the polymorphisms and age or family history of breast cancer. In conclusion, our data provide persuasive evidence against an overall association between invasive breast cancer risk and ERCC4 rs744154, TNF rs361525, CASP10 rs13010627, PGR rs1042838, and BID rs8190315 genotypes among women of European descent.
U2 - 10.1158/1055-9965.EPI-08-0745
DO - 10.1158/1055-9965.EPI-08-0745
M3 - Journal article
C2 - 19423537
SN - 1055-9965
VL - 18
SP - 1610
EP - 1616
JO - Cancer Epidemiology, Biomarkers & Prevention
JF - Cancer Epidemiology, Biomarkers & Prevention
IS - 5
ER -